Verily IPO
Verily Life Sciences is Alphabet's life sciences subsidiary focused on using technology and data science to improve health outcomes. The company develops digital health tools, conducts clinical research, and creates medical devices and software platforms. Investors are interested in its potential to revolutionize healthcare through data analytics and precision medicine.
What We Know
Verily has not announced plans for an IPO, though as an Alphabet subsidiary, there has been periodic speculation about potential spin-offs of various Alphabet divisions. The company operates as a separate entity within Alphabet's "Other Bets" segment and has established partnerships with major healthcare organizations and pharmaceutical companies. While Verily has significant resources and backing from Alphabet, no formal IPO process or timeline has been announced. The company would likely need to demonstrate clear paths to profitability and substantial market traction before considering independence from its parent company through a public offering.
Frequently Asked Questions
Has Verily had an IPO?
No, Verily has not had an IPO and remains a subsidiary of Alphabet Inc. The company operates as part of Alphabet's "Other Bets" division.
When is the Verily IPO date?
Verily has not announced any IPO plans or timeline for going public independently. As an Alphabet subsidiary, any IPO would require corporate restructuring decisions. Sign up for alerts to stay informed.
How can I buy Verily stock?
You cannot buy Verily stock directly, but you can invest in its parent company Alphabet Inc. (GOOGL/GOOG). If Verily spins off independently, it would become available through brokers. Sign up for alerts to stay informed.
Stay Updated on the Verily IPO
Get real-time alerts when Verily files for an IPO, prices shares, or begins trading.
Get IPO Alerts